Search results for "TUMORS"

showing 10 items of 1138 documents

A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuva…

2009

Abstract Background Aromatase (CYP19A1) regulates estrogen biosynthesis. Polymorphisms in CYP19A1 have been related to the pathogenesis of breast cancer (BC). Inhibition of aromatase with letrozole constitutes the best option for treating estrogen-dependent BC in postmenopausal women. We evaluate a series of polymorphisms of CYP19A1 and their effect on response to neoadjuvant letrozole in early BC. Methods We analyzed 95 consecutive postmenopausal women with stage II-III ER/PgR [+] BC treated with neoadjuvant letrozole. Response to treatment was measured by radiology at 4th month by World Health Organization (WHO) criteria. Three polymorphisms of CYP19A1, one in exon 7 (rs700519) and two in…

OncologyCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentAnastrozoleAntineoplastic AgentsBreast Neoplasmslcsh:RC254-282AromataseBreast cancerSurgical oncologyInternal medicineNitrilesGeneticsmedicineHumansAromatase3' Untranslated RegionsNeoadjuvant therapyAgedAged 80 and overPolymorphism GeneticAromatase inhibitorbiologybusiness.industryLetrozoleMiddle AgedTriazoleslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseImmunohistochemistryNeoadjuvant TherapyPostmenopauseTreatment OutcomeEndocrinologyOncologyLetrozoleDisease Progressionbiology.proteinFemalebusinessTamoxifenResearch Articlemedicine.drugBMC Cancer
researchProduct

Treatment of embryonal tumors with multilayered rosettes with carboplatin/etoposide induction and high-dose chemotherapy within the prospective P-HIT…

2021

Abstract Background Embryonal tumors with multilayered rosettes (ETMR) are highly aggressive tumors occurring in early childhood. Published clinical data refer to retrospective, heterogeneously treated cohorts. Here, we describe the outcome of patients treated according to the prospective P-HIT trial and subsequent HIT2000-interim-registry. Patients and methods Age-stratified treatment included carboplatin/etoposide induction, tandem high-dose chemotherapy (“CARBO/ETO + HDCT”), and response-stratified radiotherapy. Patients with centrally reviewed neuropathological and molecularly confirmed diagnosis of ETMR recruited within the P-HIT trial (2001-2011; n = 19), the HIT2000-interim-registry …

OncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentMedizinClinical InvestigationsImproved survival610 Medicine & healthBrain Neoplasms/drug therapyCentral Nervous System NeoplasmsHigh dose chemotherapychemistry.chemical_compoundCarboplatin/therapeutic useInternal medicinemedicineHigh-dose chemotherapyHumansNeuroectodermal Tumors Primitive1306 Cancer ResearchProspective StudiesChildOutcomeEtoposideRetrospective StudiesChemotherapyddc:618business.industryBrain NeoplasmsIncidence (epidemiology)IncidenceInfantInduction ChemotherapyNeoplasms Germ Cell and EmbryonalCarboplatinETMRRadiation therapyClinical trialClinical trial2728 Neurology (clinical)Oncologychemistry10036 Medical ClinicChild Preschool2730 OncologyNeurology (clinical)Antineoplastic Combined Chemotherapy Protocols/therapeutic usebusinessCarboplatin/etoposideNeoplasms Germ Cell and Embryonal/drug therapy
researchProduct

Moving the target on the optimal adjuvant strategy for resected pancreatic cancers: A systematic review with meta-analysis

2020

Combination regimens have shown superiority over single agents in the adjuvant treatment of resected pancreatic cancer (PC), but there are no data supporting definition of the best regimen. This work aimed to compare the efficacy and safety of mFOLFIRINOX, gemcitabine+capecitabine, and gemcitabine+nab/paclitaxel in PC patients. A meta-analysis was performed for direct comparison between trials comparing combination regimens and gemcitabine monotherapy. Subsequently, an indirect comparison was made between trials investigating the efficacy and safety of mFOLFIRINOX, gemcitabine+capecitabine, and gemcitabine+nab/paclitaxel because of the same control arm (gemcitabine). A total of three studie…

OncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentReviewNeutropenialcsh:RC254-282Capecitabine03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePancreatic cancerInternal medicinemedicineChemotherapyMeta-analysi030212 general & internal medicineAdjuvantChemotherapybusiness.industryMFOLFIRINOXPancreatic cancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseGemcitabineRegimenMeta-analysisOncologyPaclitaxelchemistryAdjuvant Chemotherapy Meta-analysis MFOLFIRINOX Pancreatic cancer Systematic review030220 oncology & carcinogenesisSystematic reviewbusinessAdjuvantmedicine.drug
researchProduct

Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma

2020

Background: Radiology-based outcomes, such as progression-free survival (PFS) and objective response rate (ORR), are used as surrogate endpoints in oncology trials. We aimed to assess the surrogacy relationship of PFS with overall survival (OS) in clinical trials of systemic therapies targeting advanced hepatocellular carcinoma (HCC) by novel meta-regression methods. Methods: A search of databases (PubMed, American Society of Clinical Oncology (ASCO), and European Society for Medical Oncology (ESMO) Meeting Libraries, Clinicaltrials.gov) for trials of systemic therapies for advanced HCC reporting both OS and PFS was performed. Individual patient data were extracted from PFS and OS Kaplan&nd…

OncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentoverall survivallcsh:RC254-282ArticleSettore MED/01 - Statistica Medica03 medical and health sciences0302 clinical medicineInternal medicinesurrogate endpointmedicineOverall survival030212 general & internal medicineProgression-free survivalneoplasmsSettore MED/12 - Gastroenterologiabusiness.industrySurrogate endpointImmunotherapyhepatocellular carcinomamedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensConfidence intervalClinical trialOncologyQuartile030220 oncology & carcinogenesisHepatocellular carcinomasurrogate endpointsimmunotherapySettore SECS-S/01 - Statisticabusinessprogression-free survivalCancers
researchProduct

Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis

2020

Background: Although the use of adjuvant chemotherapy (AC) appears to be increasing over the past few years, several clinical trials and previous meta-analyses failed to determine whether AC could improve clinical outcomes in uterine leiomyosarcoma (uLMS). The aim of this systematic review and meta-analysis was to compare AC (with or without radiotherapy) versus observation (obs) after primary surgery in early stage uLMS. Materials and Methods: Randomized controlled (RCTs) and non-randomized studies (NRSs) were retrieved. Outcomes of interest were as follows: distant recurrence rate, locoregional recurrence rate and overall recurrence rate. Results about distant recurrence rate, locoregiona…

OncologyCancer Researchmedicine.medical_specialtyuterine sarcomamedicine.medical_treatmentchemotherapylcsh:RC254-282meta-analysiArticleNOuterine leiomyosarcoma03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdjuvant therapy030212 general & internal medicineStage (cooking)meta-analysis uterine leiomyosarcoma uterine sarcoma adjuvant therapy chemotherapyUterine sarcomabusiness.industryadjuvant therapyOdds ratiomedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensConfidence intervalClinical trialRadiation therapymeta-analysisadjuvant therapy chemotherapyOncology030220 oncology & carcinogenesisMeta-analysisAdjuvant therapy Uterine sarcoma Uterine leiomyosarcoma Meta-analysis ChemotherapybusinessCancers
researchProduct

Radiomic analysis reveals DCE-MRI features for prediction of molecular subtypes of breast cancer.

2017

The purpose of this study was to investigate the role of features derived from breast dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and to incorporated clinical information to predict the molecular subtypes of breast cancer. In particular, 60 breast cancers with the following four molecular subtypes were analyzed: luminal A, luminal B, human epidermal growth factor receptor-2 (HER2)-over-expressing and basal-like. The breast region was segmented and the suspicious tumor was depicted on sequentially scanned MR images from each case. In total, 90 features were obtained, including 88 imaging features related to morphology and texture as well as dynamic features from tumor and …

OncologyCancer Treatmentlcsh:MedicineInvasive Ductal CarcinomaLogistic regression030218 nuclear medicine & medical imagingDiagnostic Radiology0302 clinical medicineMathematical and Statistical TechniquesBreast TumorsImage Processing Computer-AssistedMedicine and Health Scienceslcsh:ScienceMultidisciplinarymedicine.diagnostic_testHuman epidermal growth factorRadiology and ImagingMiddle AgedMagnetic Resonance ImagingOncology030220 oncology & carcinogenesisArea Under CurvePhysical SciencesFemaleAlgorithmsStatistics (Mathematics)Research ArticleAdultmedicine.medical_specialtyImaging TechniquesImage processingBreast NeoplasmsResearch and Analysis MethodsCarcinomasSkewness03 medical and health sciencesBreast cancerText miningDiagnostic MedicineInternal medicineImage Interpretation Computer-AssistedBreast CancermedicineBiomarkers TumorHumansStatistical MethodsDifferentiated TumorsAgedNeoplasm StagingReceiver operating characteristicbusiness.industrylcsh:RCancers and NeoplasmsMagnetic resonance imagingLuminal amedicine.diseaseImage EnhancementProbability TheoryProbability Distributionlcsh:QNeoplasm GradingbusinessMathematicsForecastingPloS one
researchProduct

Distinct Mutational Profile of Lynch Syndrome Colorectal Cancers Diagnosed under Regular Colonoscopy Surveillance

2021

Regular colonoscopy even with short intervals does not prevent all colorectal cancers (CRC) in Lynch syndrome (LS). In the present study, we asked whether cancers detected under regular colonoscopy surveillance (incident cancers) are phenotypically different from cancers detected at first colonoscopy (prevalent cancers). We analyzed clinical, histological, immunological and mutational characteristics, including panel sequencing and high-throughput coding microsatellite (cMS) analysis, in 28 incident and 67 prevalent LS CRCs (n total = 95). Incident cancers presented with lower UICC and T stage compared to prevalent cancers (p &lt

OncologyColorectal cancerColonoscopybiomarkkeritHEREDITARYGUIDELINESTp53 mutationmedicine.disease_causeMolecular level0302 clinical medicineRISKincident cancercancer preventionmedicine.diagnostic_testRGeneral MedicineTUMORSLynch syndrome3. Good healthsyöpäsolutCARCINOMAS030220 oncology & carcinogenesisMedicineDNA mismatch repair030211 gastroenterology & hepatologyKRAScarcinogenesiskoloskopiamedicine.medical_specialtyDATABASEcolorectal cancersuolistosyövätmikrosatelliititArticle03 medical and health sciencescolonoscopy screeningInternal medicinemutational profilingmedicineLynchin oireyhtymäPathologicalpaksusuolisyöpäCancer preventionmismatch repair deficiencybusiness.industryMicrosatellite instabilitySCREENING INTERVAL3126 Surgery anesthesiology intensive care radiologymedicine.diseasedigestive system diseasesMSH2Lynch syndromeMSH23121 General medicine internal medicine and other clinical medicineT-stageCLINICAL MANAGEMENTmicrosatellite instabilitymutaatiotbusinessJournal of Clinical Medicine
researchProduct

Associations between aromatase CYP19 rs10046 polymorphism and breast cancer risk: from a case-control to a meta-analysis of 20,098 subjects.

2012

Lifetime exposure to estrogen is a factor that plays an important role in the pathogenesis and progression of breast cancer. Genetic variants in genes of the biosynthesis and metabolism of estrogen have been associated with breast cancer risk. Among them, the CYP19 gene encodes for aromatase, the enzyme that catalyzes the conversion of androgens to estrogens. The rs10046 polymorphism on the CYP19 gene has been related to levels of circulating estradiol and to the estradiol/testosterone ratio. To date, epidemiological studies of rs10046 have been performed in different populations with contradictory results. In the present study, we have conducted a case-control analysis (522 cases and 1221 …

OncologyEpidemiologylcsh:MedicineBreast TumorsAromataselcsh:ScienceAged 80 and overMultidisciplinarybiologyObstetrics and GynecologyMiddle AgedOncologyMeta-analysisMedicineFemaleCancer EpidemiologyResearch ArticleAdultmedicine.medical_specialtyAdolescentmedicine.drug_classBreast NeoplasmsPolymorphism Single NucleotideYoung AdultBreast cancerAromataseInternal medicineGenetic modelBreast CancermedicineGeneticsHumansGenetic Predisposition to DiseaseAlleleBiologyAgedPopulation Biologylcsh:RCase-control studyReproducibility of ResultsCancers and NeoplasmsOdds ratiomedicine.diseaseEndocrinologyEstrogenCase-Control Studiesbiology.proteinGenetic PolymorphismWomen's Healthlcsh:QPopulation GeneticsPLoS ONE
researchProduct

Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study

2019

Background: In real-world practice, eribulin mesylate provides significant survival benefit, with a manageable safety profile in heavily pretreated patients with metastatic breast cancer (MBC). Methods: In this prospective, open-label, multicentre, observational study we evaluated the effectiveness and tolerability of eribulin as third-line treatment in a homogeneous population. The primary endpoints were the safety profile and response in metastatic sites; secondary endpoints included the response in different subtypes, overall response rate (ORR), progression-free survival (PFS) and overall survival (OS). Results: From 2013 to 2016, 118 women were treated in 21 Sicilian institutions; the …

OncologyEribulin Mesylatemedicine.medical_specialtymulticentreThird-line therapylcsh:RC254-282chemistry.chemical_compoundInternal medicinemedicineIn patienteribulin metastatic breast cancer multicentre prospective real world third lineeribulinthird lineOriginal Researchbusiness.industryreal worldprospectivemedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensMetastatic breast cancerSafety profileSurvival benefitOncologychemistryObservational studymetastatic breast cancerbusinessEribulinTherapeutic Advances in Medical Oncology
researchProduct

Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Reg…

2015

Background The European Association for the Study of the Liver (EASL) criteria and the modified Response Evaluation Criteria in Solid Tumors (mRECIST) are currently adopted to evaluate radiological response in patients affected by HCC and treated with loco-regional procedures. Several studies explored the validity of these measurements in predicting survival but definitive data are still lacking. Aim To conduct a systematic review of studies exploring mRECIST and EASL criteria usefulness in predictive radiological response in HCC undergoing loco-regional therapies and their validity in predicting survival. Methods A comprehensive search of the literature was performed in electronic database…

OncologyGenetics and Molecular Biology (all)medicine.medical_specialtyCarcinoma HepatocellularPrognosiConcordancePopulationMEDLINElcsh:MedicineCarcinoma Hepatocellular; Humans; Liver Neoplasms; Prognosis; Survival Analysis; Treatment Outcome; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Cochrane LibraryBiochemistryInternal medicinemedicineHumanseducationlcsh:ScienceSurvival analysiseducation.field_of_studyMultidisciplinaryBiochemistry Genetics and Molecular Biology (all)Carcinoma Hepatocellular; Humans; Liver Neoplasms; Prognosis; Survival Analysis; Treatment Outcome; Agricultural and Biological Sciences (all); Biochemistry Genetics and Molecular Biology (all); Medicine (all)business.industryMedicine (all)CarcinomaLiver Neoplasmslcsh:RHepatocellularPrognosisSurvival AnalysisConfidence intervalSurgeryTreatment OutcomeAgricultural and Biological Sciences (all)Response Evaluation Criteria in Solid TumorsLiver NeoplasmMeta-analysislcsh:QSurvival AnalysibusinessHumanResearch ArticlePLoS ONE
researchProduct